Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TELA Bio (TELA)
NASDAQ:TELA
Holding TELA?
Track your performance easily
TELA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $7.84
Previous CloseN/A
Volume34.27K
Average Volume (3M)167.65K
Market Cap
$104.77M
Enterprise Value$86.73M
Total Cash (Recent Filing)$11.35M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 19, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding39,388,443
10 Day Avg. Volume95,900
30 Day Avg. Volume167,647
Standard Deviation0.16
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.53
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-1.91
Forecast
1Y Price Target
$9.25Price Target Upside243.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
TELA Bio News
PremiumCompany Announcements
TELA Bio, Inc. Reports Record Revenue Growth
PremiumCompany Announcements
TELA Bio Achieves Record Q3 Revenue Growth in 2024
PremiumCompany Announcements
TELA Bio Reports Q3 2024 Preliminary Financial ResultsBulls Say, Bears Say
Bulls Say
Litigation SettlementThe settlement of BD's hernia mesh lawsuits is expected to drive a shift in preference towards natural repair solutions, benefiting TELA's OviTex.
Market CompetitivenessTELA launched its inguinal hernia repair product line with pricing closer to synthetic mesh options, enhancing its market competitiveness.
Product PortfolioCombining a robust product portfolio with an increasingly seasoned salesforce, expanding GPO implementation, and robotic adoption tailwinds, TELA is nearing an inflection point in its business.
Bears Say
Cybersecurity IssuesA ransomware attack at the company's most recently signed GPO, covering approximately 150 hospitals, resulted in a financial hit of $1.25 million to $1.75 million.
Financial PerformanceQ2 revenue of $16.1M was below the Street’s expectation of $18.4M, breaking the three-year-plus quarterly trend of delivering sales growth in excess of 35%.
Operational ChallengesTELA missed top- and bottom-line expectations due to unexpected roadblocks including two cybersecurity attacks and the departure of three of its surgeon users.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $2.30 and its highest was $7.84 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $104.77M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Mar 19, 2025 which is in 59 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Nov 07, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.405 by -$0.015.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.21.
How many shares outstanding does TELA Bio have?
TELA Bio has 39,388,443 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.405. Following the earnings report the stock price went up 3.01%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
---
TELA Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.25 (243.87% Upside)
$9.25 (243.87% Upside)
Blogger Sentiment
Bullish
TELA Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $265.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.73%
12-Months-Change
Fundamentals
Return on Equity
-342.03%
Trailing 12-Months
Asset Growth
-39.28%
Trailing 12-Months
Company Description
TELA Bio
TELA Bio, Inc. is a commercial stage medical technology company. It focuses on designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. TELA Bio was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
---
TELA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and market expansion, particularly in Europe, along with a successful public offering and operational improvements. However, there were concerns about decreased gross margins, increased sales and marketing expenses, and ongoing net losses. The company remains optimistic with positive revenue guidance for the full year.Read More>---
TELA Stock 12 Month Forecast
Average Price Target
$9.25
▲(243.87% Upside)
Technical Analysis
AxoGen
―
Fate Therapeutics
―
RegenXBio
―
Scholar Rock Holding
―
Atara Biotherapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering TELA
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-17.53%
reiterated a buy rating 2 months ago
Copying David Turkaly's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -17.53% per trade.
---